Atg1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ATG1 / ULK1 |
|---|
| Gene Symbol | ATG1 (ULK1 in mammals) |
| Full Name | Unc-51 Like Autophagy Activating Kinase 1 |
| Chromosomal Location | 12q13.12 |
| NCBI Gene ID | 54973 |
| UniProt ID | Q9Y4P5 |
| Protein Type | Serine/Threonine Kinase |
| Molecular Weight | ~105 kDa |
ATG1 (known as ULK1 in mammals) is the founding member of the ULK kinase complex and serves as the master initiator of autophagy. This serine/threonine kinase coordinates the recruitment and activation of the entire autophagy machinery in response to cellular stress, nutrient deprivation, and energy depletion. ULK1 is evolutionarily conserved from yeast (ATG1) to humans and is essential for autophagosome formation.
¶ Function and Mechanism
ULK1 forms a core complex with ATG13, FIP200, and ATG101 (also known as RB1CC1). This ULK1-ATG13-FIP200-ATG101 complex is the primary sensor of nutrient and energy status in cells:
- ULK1: Catalytic serine/threonine kinase that initiates autophagy signaling
- ATG13: Regulatory subunit that enhances ULK1 activity and serves as a scaffold
- FIP200: Scaffold protein that recruits downstream effectors
- ATG101: Stabilizing subunit that protects ATG13 from degradation
Upon starvation or mTOR inhibition, ULK1 phosphorylates multiple downstream targets:
- Beclin-1 phosphorylation (Ser14) — Activates the class III PI3K complex (PIK3C3/VPS34) to generate PI3P on isolation membranes
- ATG14L phosphorylation — Targets the PI3K complex to the ER-associated omegasomes
- VPS34 phosphorylation — Directly enhances lipid kinase activity
- ATG4B phosphorylation — Regulates LC3 lipination by modulating ATG4 protease activity
- ATG9 phosphorylation — Promotes the cycling of the transmembrane protein ATG9 between Golgi and autophagosomes
ULK1 is activated by AMP-activated protein kinase (AMPK) when cellular energy is low:
- AMPK phosphorylates ULK1 at multiple serine residues (Ser317, Ser555, Ser777)
- This activates ULK1 to initiate autophagy and restore energy homeostasis
In AD, ULK1-mediated autophagy is dysregulated at multiple levels:
- Amyloid-beta impact: Aβ accumulation suppresses ULK1 activity through mTOR hyperactivation, impairing autophagic clearance
- Tau pathology: ULK1 phosphorylates tau at multiple sites; dysregulated ULK1 may contribute to abnormal tau aggregation
- Autophagy-lysosomal dysfunction: ULK1-dependent autophagosome formation is impaired in AD neurons
- Therapeutic targeting: Small molecule ULK1 activators (e.g., LTB4 agonists) promote Aβ clearance in preclinical models
ULK1 plays critical roles in PD pathogenesis:
- Mitophagy regulation: ULK1 phosphorylates PINK1 and Parkin to coordinate mitophagy of damaged mitochondria
- Alpha-synuclein clearance: ULK1 activity is required for the autophagic degradation of alpha-synuclein aggregates
- LRRK2 interaction: ULK1 phosphorylates LRRK2 at Ser910/Ser935, regulating its subcellular localization
- Genetic susceptibility: ULK1 polymorphisms are associated with sporadic PD risk
- TDP-43 aggregates: ULK1-mediated mitophagy is impaired in TDP-43 ALS models
- C9orf72: The ULK1 complex interacts with C9orf72 in regulating autophagy
- FUS mutations: ULK1 activity is reduced in FUS-ALS, contributing to defective autophagy
- Huntington's Disease: ULK1 activity is beneficial for clearing mutant huntingtin protein aggregates
- Prion Diseases: ULK1-mediated autophagy is suppressed in prion-infected neurons
- Multiple System Atrophy: ULK1 dysregulation contributes to oligodendrocyte degeneration
| Approach |
Mechanism |
Status |
| ULK1 agonists |
Activate autophagy to clear protein aggregates |
Preclinical |
| mTOR inhibitors |
Indirectly activate ULK1 by relieving inhibition |
Approved (rapamycin) |
| AMPK activators |
Directly phosphorylate and activate ULK1 |
Research |
| Gene therapy |
Overexpress ULK1 in target neurons |
Preclinical |
- Positive regulators: AMPK, mTOR (inhibition releases ULK1), p53
- Negative regulators: mTORC1, Akt
- Downstream effectors: Beclin-1, ATG14L, ATG13, LC3, ATG9
- Disease proteins: α-synuclein, tau, TDP-43, mutant huntingtin
The study of Atg1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mizushima et al., The role of ATG proteins in autophagosome formation (2020)
- Egan et al., Phosphorylation of the ULK1 complex in autophagy (2011)
- Wang et al., ULK1 phosphorylates Beclin-1 to activate autophagy (2018)
- Jiang et al., ULK1 in neurodegenerative disease (2021)
- Wu et al., ULK1-mediated mitophagy in Parkinson's disease (2020)